SCHEDULE: Sirenia Capital Management Discloses Xilio Therapeutics Stake

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Xilio Therapeutics, Inc. common stock, primarily through exercisable warrants.

Summary

• Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, indicating their beneficial ownership of Xilio Therapeutics, Inc. common stock.
• The filing reports a beneficial ownership of 1,142,862 shares, representing 9.9% of the outstanding common stock as of March 18, 2026.
• This ownership is primarily derived from exercisable warrants, with a '9.99% Blocker' provision limiting the exercise of these warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates a significant investment position via warrants but lacks details on the company's performance or the specific terms of the investment, making a strong positive or negative sentiment difficult to ascertain.

Positives

• Sirenia Capital Management LP and Alex Silverstein have disclosed a significant stake in Xilio Therapeutics, Inc., potentially signaling confidence in the company's future.
• The reporting persons are classified as investment adviser (IA) and hedge fund/investment company (PN, HC, IN), suggesting sophisticated investment strategies.
• The disclosure is made in accordance with regulatory requirements, ensuring transparency for investors.

Negatives

• The beneficial ownership is largely tied to warrants, which are contingent on exercise and subject to limitations (the 9.99% Blocker), meaning actual ownership may be less than reported if not all warrants can be exercised.
• The filing does not provide details on the specific terms or expiration dates of the warrants, making it difficult to assess their immediate value or potential dilution.

Risks

• The '9.99% Blocker' on warrant exercise poses a risk of not being able to fully capitalize on the potential upside if the ownership threshold is reached.
• The reliance on warrants for a significant portion of the reported ownership introduces uncertainty regarding the final number of shares held.
• The filing does not detail the specific reasons for acquiring the warrants or the investment thesis, leaving potential risks related to the underlying company performance unaddressed.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company. The outlook for Sirenia Capital Management LP and Alex Silverstein is tied to the performance of Xilio Therapeutics, Inc. and the exercise of their warrants, subject to the 9.99% Blocker.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein."
• "Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement... pursuant to which they have agreed to file this Schedule 13G jointly."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings by investment managers like Sirenia Capital Management LP are common for significant passive stakes, often acquired through warrants or convertible securities. This filing indicates a notable interest in Xilio Therapeutics, Inc. within the biotechnology sector, a field characterized by high growth potential and inherent volatility.

Stakeholder Impact

• Shareholders of Xilio Therapeutics, Inc.: The disclosure of a significant stake by an investment manager may be viewed positively, suggesting external validation, but the reliance on warrants and the 9.99% Blocker introduce complexity.
• Potential Investors: This filing provides transparency regarding a substantial beneficial owner, aiding in investment analysis.
• Sirenia Capital Management LP and Alex Silverstein: Their investment strategy and potential returns are directly linked to the performance of Xilio Therapeutics, Inc.

Next Steps

• Monitor Xilio Therapeutics, Inc.'s performance and any future disclosures regarding warrant exercise or changes in beneficial ownership.
• Observe potential future filings from Sirenia Capital Management LP and Alex Silverstein regarding their stake in Xilio Therapeutics, Inc.

Key Dates

Keywords

Schedule 13G, Xilio Therapeutics, Sirenia Capital Management LP, Alex Silverstein, Beneficial Ownership, Warrants, SEC Filing, Investment, Common Stock, 9.99% Blocker